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Background: Cardiac troponins and N-terminal pro-brain natriuretic peptide (NTproBNP) are useful for identifying chest pain patients at high risk. 
The aim was to examine whether early serial measurements of high sensitive troponin could further improve early risk stratification.
Methods: Troponin levels were determined by high sensitive troponin T (HsTnT), conventional TnT (Roche Diagnostics) and troponin I (Accu TnI, 
Beckman) assays on admission and at 2 hours in 231 consecutive chest pain patients with no ST-elevations. Patients were followed regarding death, 
rehospitalisation because of myocardial infarction(MI) or heart failure(HF).
Results: In ROC analyses, the maximum levels of HsTnT and NTproBNP provided the best diagnostic value. There was no additive value of 
measuring the change of levels. By combining HsTnT and NTproBNP patients could be divided into low-, intermediate- and high-risk groups (table). 
After adjusting for differences in baseline data, both log HsTnT (HR:1.4(1.1-1.7)) and log NTproBNP (HR:1.8(1.4-2.3)) predicted long-term outcome. 
When the prognostic value of HsTnT was compared with that of conventional TnT and TnI I in ROC analyses the AUCs(95%CI) at 3 months (0.78(0.69-
0.88), 0.79(0.70-0.88), 0.75(0.64-0.85))and at 24 months (0.73(0.65-0.80), 0.72(0.65-0.80), 0.69(0.61-0.77)) were similar.
Conclusion: The early use of cardiac troponins and NTproBNP provides excellent prognostic information in chest pain patients, but the additive 
value of Hs-TnT is limited.
Table
HsTnT<14 and NTproBNP
≤300
(n=68)
HsTnT<14 and NTproBNP>300
(n=14)
HsTnT
≥14 and NTproBNP
≤300
(n=42)
HsTnT
≥14 and NTproBNP>300
(n=99)
3 months
Death, MI, or HF
1(1.5%) 0(0%) 1(2.4%) 17(17.2%)
24 months
Death, MI, or HF
1(1.5%) 2(14.3%) 3(7.1%) 34(34.3%)
